AbbVie Wins European Commission Approval of AQUIPTA (atogepant) for the Preventive Treatment of Migraine in Adults
Portfolio Pulse from Benzinga Newsdesk
AbbVie has received approval from the European Commission for AQUIPTA (atogepant) for the preventive treatment of migraine in adults. This makes AQUIPTA the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist treatment in the European Union for the preventive treatment of both chronic and episodic migraine.
August 17, 2023 | 7:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's AQUIPTA has been approved by the European Commission for the preventive treatment of migraine in adults. This could potentially increase the company's market share in the European Union.
The approval of AQUIPTA by the European Commission opens up a new market for AbbVie in the European Union. This could potentially increase the company's revenues and market share in the region, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100